VANCOUVER, British Columbia, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce Be Trū Organics™ has commenced the process of distributing product to Erewhon Natural Foods, a premier supermarket chain in California.



“We are always looking for new ways to expand our company’s reach and further diversify our product offerings,” said Marcos Agramont, CEO of Isodiol. “We closed the 100% acquisition of Be Trū last week, and in this short amount of time, we have already seen strong results from this partnership. This partnership will continue to open additional revenue streams, and enable Isodiol to penetrate the mainstream market and provide consumers with natural, high-quality, health and wellness products.”

Since the late 1960s, Erewhon has been committed to providing foods and products that change the lives of consumers. Erewhon sets the standard for the highest quality ingredients possible and endlessly works towards providing their consumers with the best foods and products the earth can offer.

“Be Trū is very pleased to share this update and we expect many more opportunities to present themselves in the coming months,” said Keith Gordon, CEO of Be Trū Organics. “As we move along in our partnership with Isodiol, we will begin to include their products in our distribution.”

For more information on Isodiol, please visit www.isodiol.com

For more information on Be Trū Organics™, please visit www.betruorganics.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: https://www.facebook.com/isodiol/

Twitter: @isodiol

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

Ir@isodiol.com

www.isodiol.com

MEDIA CONTACT:

Carrie Booze

North 6th Agency

212-334-9753 ext.142

Isodiol@n6a.com

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.